Profectus BioSciences has signed a research collaboration agreement with the Path Malaria Vaccine Initiative (MVI), to conduct proof-of-concept studies for a new preventative malaria vaccine.
The study will test Profectus' new vesicular stomatitis virus (rVSV) vector technology as a candidate for the new vaccine.
Profectus president and CEO Shawn Patrick O'Brien said that the company believes the vaccine technology can be successfully applied to a wide range of pathogens, including malaria.
"Malaria is a global problem that causes great human suffering. MVI's mission to accelerate the development of malaria vaccines and to ensure their availability and accessibility in the developing world is an important cause," O'Brien said
rVSV is a vaccine vector platform that can be sequentially administered in a prime-boost regimen to elicit a potent and durable immune response to target pathogens.
According to the company, the vaccine represents a significant advancement in vaccine development compared to historical DNA vaccines and adeno-virus based vectors.